Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis

  • Quirant, Bibiana|||0000-0002-3875-8074
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Fondelli, Federico|||0000-0002-6875-4744
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Autologous antigen-specific therapies based on tolerogenic dendritic cells (tolDC) offer the possibility to treat autoimmune diseases by restoring homeostasis and targeting specifically autoreactive responses. Here, we explore the hypothesis that systemic inflammation occurring in autoimmune diseases, such as multiple sclerosis (MS), can generate a disease-specific environment able to alter the functionality of tolDC. In this context in fact, a combined therapy of tolDC with an immunomodulatory treatment could potentiate the beneficial effect of this antigen-specific cell therapy. For this purpose, we analyzed the efficacy of a combined therapy based on the use of vitamin D3 (VitD3)-tolDC plus interferon beta (IFN-beta) in MS. VitD3-tolDC were generated from healthy donors and MS patients and co-cultured with allogeneic peripheral blood mononuclear cells, in the presence or absence of IFN-beta. In vitro, VitD3-tolDC treatment reduced the percentage of activated T cells and allogeneic proliferation, whereas VitD3-tolDC+IFN-beta treatment enhanced the suppressive ability of VitD3-tolDC and, additionally, induced a shift towards a Th2 profile. To determine the clinical benefit of the combined therapy, C57BL/6-experimental autoimmune encephalomyelitis (EAE)-induced mice were treated with antigen-specific VitD3-tolDC and/or IFN-beta. Treatment of EAE mice with combined therapy ameliorated the disease course compared to each monotherapy. These results suggest that a combined therapy based on antigen-specific VitD3-tolDC and IFN-beta may represent a promising strategy for MS patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ways forward for tolerance-inducing cellular therapies- An afactt perspective

  • Ten Brinke, Anja
  • Martinez-Llordella, Marc
  • Cools, Nathalie|||0000-0002-0459-901X
  • Hilkens, Catharien M. U.
  • van Ham, S. Marieke
  • Sawitzki, Birgit
  • Geissler, Edward K.
  • Lombardi, Giovanna
  • Trzonkowski, Piotr
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Clinical studies with cellular therapies using tolerance-inducing cells, such as tolerogenic antigen-presenting cells (tolAPC) and regulatory T cells (Treg) for the prevention of transplant rejection and the treatment of autoimmune diseases have been expanding the last decade. In this perspective, we will summarize the current perspectives of the clinical application of both tolAPC and Treg, and will address future directions and the importance of immunomonitoring in clinical studies that will result in progress in the field.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS), A harmonised study protocol for two phase i clinical trials comparing intradermal and intranodal cell administration

  • Willekens, Barbara|||0000-0002-5212-8837
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Derdelinckx, Judith
  • Lee, Wai-Ping|||0000-0001-9113-7317
  • Nijs, Griet
  • De Laere, Maxime
  • Wens, Inez
  • Cras, Patrick|||0000-0002-7265-7429
  • Parizel, Paul
  • Van Hecke, Wim
  • Ribbens, Annemie
  • Billiet, Thibo
  • Adams, Geert
  • Couttenye, Marie-Madeleine
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Lopez-Diaz De Cerio, Ascensión
  • Inogés, Susana
  • Prosper, Felipe|||0000-0001-6115-8790
  • Kip, Anke
  • Verheij, Herman
  • Gross, Catharina C.
  • Wiendl, Heinz|||0000-0003-4310-3432
  • Van Ham, Marieke
  • Ten Brinke, Anja
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Massuet-Vilamajó, Anna
  • Hens, Niel
  • Berneman, Zwi
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Cools, Nathalie|||0000-0002-0459-901X
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
Introduction Based on the advances in the treatment of multiple sclerosis (MS), currently available disease-modifying treatments (DMT) have positively influenced the disease course of MS. However, the efficacy of DMT is highly variable and increasing treatment efficacy comes with a more severe risk profile. Hence, the unmet need for safer and more selective treatments remains. Specifically restoring immune tolerance towards myelin antigens may provide an attractive alternative. In this respect, antigen-specific tolerisation with autologous tolerogenic dendritic cells (tolDC) is a promising approach. Methods and analysis Here, we will evaluate the clinical use of tolDC in a well-defined population of MS patients in two phase I clinical trials. In doing so, we aim to compare two ways of tolDC administration, namely intradermal and intranodal. The cells will be injected at consecutive intervals in three cohorts receiving incremental doses of tolDC, according to a best-of-five design. The primary objective is to assess the safety and feasibility of tolDC administration. For safety, the number of adverse events including MRI and clinical outcomes will be assessed. For feasibility, successful production of tolDC will be determined. Secondary endpoints include clinical and MRI outcome measures. The patients' immune profile will be assessed to find presumptive evidence for a tolerogenic effect in vivo. Ethics and dissemination Ethics approval was obtained for the two phase I clinical trials. The results of the trials will be disseminated in a peer-reviewed journal, at scientific conferences and to patient associations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MAP7 and MUCL1 are biomarkers of Vitamin D3-induced tolerogenic dendritic cells in multiple sclerosis patients

  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Ardiaca-Martínez, Alicia
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Ten Brinke, Anja
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The administration of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases, such as multiple sclerosis (MS). Specifically, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most widely studied approaches, as it has evidenced significant immune regulatory properties, both in vitro and in vivo. In this article, we generated human vitD3-tolDC from monocytes from healthy donors and MS patients, characterized in both cases by a semi-mature phenotype, secretion of IL-10 and inhibition of allogeneic lymphocyte proliferation. Additionally, we studied their transcriptomic profile and selected a number of differentially expressed genes compared to control mature and immature dendritic cells for their analysis. Among them, qPCR results validated CYP24A1, MAP7 and MUCL1 genes as biomarkers of vitD3-tolDC in both healthy donors and MS patients. Furthermore, we constructed a network of protein interactions based on the literature, which manifested that MAP7 and MUCL1 genes are both closely connected between them and involved in immune-related functions. In conclusion, this study evidences that MAP7 and MUCL1 constitute robust and potentially functional biomarkers of the generation of vitD3-tolDC, opening the window for their use as quality controls in clinical trials for MS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator

  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Figa-Martín, Neus
  • Barallat, Jaume|||0000-0003-3493-5958
  • Fondelli, Federico|||0000-0002-6875-4744
  • Sellés-Rius, Ares|||0000-0002-9745-7749
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The use of autologous tolerogenic dendritic cells (tolDC) has become a promising strategy to re-establish immune tolerance in autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (VitD3-tolDC) has been widely tested because of their immune regulatory properties. To identify molecules and pathways involved in the generation of VitD3-tolDC, we established an easy and fast gene silencing method based on the use of Viromer blue to introduce siRNA into monocytes on day 1 of culture differentiation. The analysis of the effect of CD209 (DC-SIGN) and CD115 (CSF1R) down-modulation on the phenotype and functionality of transfected VitD3-tolDC revealed a partial role of CD115 in their tolerogenicity. Further investigations showed that CSF1R-CSF1 signaling is involved in the induction of cell metabolic reprogramming, triggering glycolysis to produce high amounts of lactate, a novel suppressive mechanism of T cell proliferation, recently found in autologous tolerogenic dendritic cells (ATDCs).